HSTO.Q Stock Overview
A clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Histogen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.21 |
| 52 Week High | US$0.55 |
| 52 Week Low | US$0.05 |
| Beta | 1.12 |
| 11 Month Change | -28.33% |
| 3 Month Change | -3.37% |
| 1 Year Change | -36.76% |
| 33 Year Change | -97.82% |
| 5 Year Change | n/a |
| Change since IPO | -99.77% |
Recent News & Updates
Recent updates
Histogen stock down 8% after Q2 loss, on track for six-day losing streak
Aug 12Histogen announces pricing of $5M private placement
Jul 12We're A Little Worried About Histogen's (NASDAQ:HSTO) Cash Burn Rate
Dec 02
Histogen jumps 11% after Intracoastal Capital reports 5.6% stake
Jun 16Histogen enters $6.5M at-the-market direct offering
Jun 07Histogen under pressure on pricing $14M upsized public offering
Dec 31Histogen files IND application for regenerative human matrix
Dec 17Histogen soars after HST-001 data in male pattern baldness
Dec 01Shareholder Returns
| HSTO.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -10.5% | -2.1% |
| 1Y | -36.8% | 12.7% | 29.7% |
Return vs Industry: HSTO.Q underperformed the US Biotechs industry which returned 12.7% over the past year.
Return vs Market: HSTO.Q underperformed the US Market which returned 29.7% over the past year.
Price Volatility
| HSTO.Q volatility | |
|---|---|
| HSTO.Q Average Weekly Movement | 18.9% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HSTO.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HSTO.Q's weekly volatility has decreased from 36% to 19% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 7 | Susan Knudson | www.histogen.com |
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. The company’s product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases.
Histogen Inc. Fundamentals Summary
| HSTO.Q fundamental statistics | |
|---|---|
| Market cap | US$918.43k |
| Earnings (TTM) | -US$12.38m |
| Revenue (TTM) | US$19.00k |
48.3x
P/S Ratio-0.1x
P/E RatioIs HSTO.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HSTO.Q income statement (TTM) | |
|---|---|
| Revenue | US$19.00k |
| Cost of Revenue | US$3.28m |
| Gross Profit | -US$3.26m |
| Other Expenses | US$9.12m |
| Earnings | -US$12.38m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.90 |
| Gross Margin | -17,152.63% |
| Net Profit Margin | -65,142.11% |
| Debt/Equity Ratio | 0% |
How did HSTO.Q perform over the long term?
See historical performance and comparison